Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

Cytoscape: A software Environment for integrated models of biomolecular interaction networks

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888

An obesity-associated gut microbiome with increased capacity for energy harvest

Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444

PLS-regression: a basic tool of chemometrics

Wold, S., Sjöström, M., & Eriksson, L. (2001) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/s0169-7439(01)00155-1 · Cited by 10,084

A core gut microbiome in obese and lean twins

Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823

Enterotypes of the human gut microbiome

MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548

Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998

Ferenci, P., Lockwood, A. H., Mullen, K. D., Tarter, R. E., Weißenborn, K., & Blei, A. T. (2002) · Hepatology · doi:10.1053/jhep.2002.31250 · Cited by 2,035

Computing topological parameters of biological networks

Assenov, Y., Ramírez, F., Schelhorn, S.-E., Lengauer, T., & Albrecht, M. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm554 · Cited by 1,805

The interplay between the intestinal microbiota and the brain

Collins, S. M., Surette, M., & Bercik, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2876 · Cited by 1,611 · cited 1×

Rifaximin Treatment in Hepatic Encephalopathy

Bass, N. M., Mullen, K. D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., Sigal, S., Sheikh, M. Y., Beavers, K., Frederick, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907893 · Cited by 1,300

pcaMethods—a bioconductor package providing PCA methods for incomplete data

Stacklies, W., Redestig, H., Scholz, M., Walther, D., & Selbig, J. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm069 · Cited by 1,156

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy

Gluud, L. L., Kimer, N., & Krag, A. A. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s41565 · Cited by 25

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota

Wang, M., Ma, W., Wang, Y., Ma, X., Xue, Y.-F., Guan, J. Z., & Chen, X. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1091167 · Cited by 26

Novel prevention strategies for bacterial infections in cirrhosis

Yan, K. G., & García–Tsao, G. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1145663 · Cited by 26

Rifaximin: A Review of Its Use in Reducing Recurrence of Overt Hepatic Encephalopathy Episodes

Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0300-y · Cited by 26

Evolving Concepts: The Negative Effect of Minimal Hepatic Encephalopathy and Role for Prophylaxis in Patients With Cirrhosis

Prakash, R. K., Kanna, S., & Mullen, K. D. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.421 · Cited by 25

Does a glucose‐based hydrogen and methane breath test detect bacterial overgrowth in the jejunum?

Sundin, O. H., Mendoza‐Ladd, A., Morales, E., Fagan, B. M., Zeng, M., Díaz-Arévalo, D., Ordoñez, J., & McCallum, R. W. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13350 · Cited by 25

Microbial Products and Metabolites Contributing to Alcohol‐Related Liver Disease

Gao, B., Emami, A., Nath, S., & Schnabl, B. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000023 · Cited by 25

Infection, inflammation and hepatic encephalopathy from a clinical perspective

Ntuli, Y., & Shawcross, D. L. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01402-y · Cited by 31

Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy

Saboo, K., Shamsaddini, A., Iyer, M. V., Hu, C., Fagan, A., Gavis, E. A., White, M. B., Fuchs, M. A., Heuman, D. M., Sikaroodi, M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.046 · Cited by 25

Effect of exposure to antibiotics on the gut microbiome and biochemical indexes of pregnant women

Su, Y., Gan, X.-P., Li, F., Zhang, D., Chen, L., Cao, Y., Qiu, H.-H., Cheng, D., Zu, J.-F., Liu, W., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002321 · Cited by 26

Clinical Management of the Microbiome in Irritable Bowel Syndrome

Andrews, C. N., Sidani, S., & Marshall, J. K. (2019) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwz037 · Cited by 25

Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease

Račkayová, V., Flatt, E., Braissant, O., Grosse, J., Capobianco, D., Mastromarino, P., McMillin, M., DeMorrow, S., McLin, V. A., & Cudalbu, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-81871-8 · Cited by 24

Antibiotic and Modulation of Microbiota

Rizzatti, G., Ianiro, G., & Gasbarrini, A. (2018) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001069 · Cited by 24

The shaping of gut immunity in cirrhosis

Muñoz, L., Caparrós, E., Albillos, A., & Francés, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139554 · Cited by 24

Effects of Rifaximin on Central Responses to Social Stress—a Pilot Experiment

Wang, H., Braun, C., & Enck, P. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0627-2 · Cited by 24

Does low‐dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study

Zeng, X., Tang, X., Sheng, X., Ni, W., Xin, H. G., Chen, W. Z., Jiang, C., Lin, Y., Shi, J. G., Shi, B., et al. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12294 · Cited by 23

Proteome profiles of vaginal fluids from women affected by bacterial vaginosis and healthy controls: outcomes of rifaximin treatment

Cruciani, F., Wasinger, V. C., Turroni, S., Calanni, F., Donders, G. G. G., Brigidi, P., & Vitali, B. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt244 · Cited by 22

Current Applications of Metabolomics in Cirrhosis

Khan, V. N., Putluri, N., Sreekumar, A., & Mindikoglu, A. L. (2018) · Metabolites · doi:10.3390/metabo8040067 · Cited by 24

The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview

Marascio, N., Caro, C. D., Quirino, A., Mazzitelli, M., Russo, E., Torti, C., & Matera, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195936 · Cited by 22

The regulatory role of bile acid microbiota in the progression of liver cirrhosis

Zhu, F., Zheng, S., Zhao, M., Shi, F., Zheng, L., & Wang, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1214685 · Cited by 22

Management of Covert Hepatic Encephalopathy

Waghray, A., Waghray, N., & Mullen, K. D. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.02.007 · Cited by 22

Neuroimaging the Microbiome-Gut–Brain Axis

Tillisch, K., & Labus, J. S. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0897-4_18 · Cited by 23

The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status

Stojić, J., Kukla, M., & Grgurević, I. (2023) · Diagnostics · doi:10.3390/diagnostics13182960 · Cited by 21

Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders

Yuan, Y., Wang, X., Xu, X., Liu, Y., CanCan, L., Meng, Y., Yang, Y., & Ma, Z. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00374 · Cited by 21

New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease

Hartmann, P., & Schnabl, B. (2021) · Seminars in Liver Disease · doi:10.1055/s-0040-1719174 · Cited by 22

Meeting the Challenge of Antimicrobial Resistance in Cirrhosis: The Invisible Threat That Lies Within

Edwards, L. A., Goldenberg, S. D., & Shawcross, D. L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.043 · Cited by 19

Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis

Bajaj, J. S., Rodríguez, M. P., Reau, A. L., Phillips, W., Fuchs, M. A., Davis, B., Sterling, R. K., Sikaroodi, M., Fagan, A., Shamsaddini, A., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-328403 · Cited by 23

Potential therapies for acute‐on‐chronic liver failure

Morrison, M. A., Artru, F., Trovato, F. M., Triantafyllou, E., & McPhail, M. J. W. (2023) · Liver International · doi:10.1111/liv.15545 · Cited by 22

The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy

Bajaj, J. S., Fagan, A., Gavis, E. A., Mousel, T., Gallagher, M. L., Puri, P., Fuchs, M. A., Davis, B., Hylemon, P. B., Zhou, H., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000384 · Cited by 20

Firmicutes/Bacteroidetes and Firmicutes/Proteobacteria ratios are associated with worse prognosis in a cohort of Latin American patients with cirrhosis

Mantovani, A., Longo, L., Thoen, R. U., Rampelotto, P. H., Salinas, R., Guerreiro, G. T. S., & Álvares‐da‐Silva, M. R. (2024) · Clinics · doi:10.1016/j.clinsp.2024.100471 · Cited by 20

Bacterial Infections in Cirrhosis

Tonon, M., Angeli, P., & Piano, S. S. (2021) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000065 · Cited by 19

The Mucosally-Adherent Rectal Microbiota Contains Features Unique to Alcohol-Related Cirrhosis

Shen, T. D., Daniel, S. G., Patel, S., Kaplan, E., Phung, L., Lemelle-Thomas, K., Chau, L., Herman, L., Trisolini, C., Stonelake, A., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1987781 · Cited by 20

Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis

Bogatic, D., Bryant, R. V., Lynch, K. D., & Costello, S. P. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17251 · Cited by 19

Diverticular Disease and Rifaximin: An Evidence-Based Review

Piccin, A., Gulotta, M., Bella, S. D., Martingano, P., Crocè, L. S., & Giuffrè, M. (2023) · Antibiotics · doi:10.3390/antibiotics12030443 · Cited by 19

Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review

Sidhu, G., Go, A., Attar, B. M., Mutneja, H. R., Arora, S. K., & Patel, S. A. (2017) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2017-000154 · Cited by 19

Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients

Zuo, Z., Fan, H., Tang, X., Chen, Y., Xun, L., Li, Y., Song, Z., & Zhai, H. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5141 · Cited by 19

Hepatic Encephalopathy

Badal, B. D., & Bajaj, J. S. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.01.003 · Cited by 19

Serum and urinary metabolomics and outcomes in cirrhosis

Bajaj, J. S., Fan, S., Thacker, L. R., Fagan, A., Gavis, E. A., White, M. B., Heuman, D. M., Fuchs, M. A., & Fiehn, O. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223061 · Cited by 18

Assessment and Management of Infection in Alcoholic Hepatitis

Vergis, N., Atkinson, S. R., & Thursz, M. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1693402 · Cited by 17

Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients

Fiorillo, A., Gallego, J., Casanova‐Ferrer, F., Urios, A., Ballester, M. P., San‐Miguel, T., Megías, J., Kosenko, E. A., Tosca-Cuquerella, J., Ríos, M.-P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914727 · Cited by 17

Gut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis

Bajaj, J. S., O’Leary, J. G., Jakab, S., Fagan, A., Sikaroodi, M., & Gillevet, P. M. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2392880 · Cited by 17

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Chang, C. (2018) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s167031 · Cited by 17

Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease

Ranjbarian, T., & Schnabl, B. (2023) · Seminars in Liver Disease · doi:10.1055/a-2145-7331 · Cited by 16

Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)

Zhu, X., Zhou, Z., & Pan, X. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1342356 · Cited by 17

The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review

DuPont, H. L. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-23 · Cited by 15

Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial

Madsen, B. S., Trebicka, J., Thiele, M. S., Israelsen, M. E., Arumugam, M., Havelund, T., & Krag, A. A. (2018) · Trials · doi:10.1186/s13063-018-2523-9 · Cited by 15

Microbial Therapy in Liver Disease: Probiotics Probe the Microbiome–Gut–Liver–Brain Axis

Victor, D. W., & Quigley, E. M. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.023 · Cited by 15

Microbial Infections as a Trigger for Acute-on-Chronic Liver Failure: A Review

Cai, Q., Liu, W., Zhu, M., & Sheng, J. (2019) · Medical Science Monitor · doi:10.12659/msm.915637 · Cited by 17

Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy

Suzuki, H., Sezaki, H., Suzuki, F., Kasuya, K., Sano, T., Fujiyama, S., Kawamura, Y., Hosaka, T., Akuta, N., Saitoh, S., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13415 · Cited by 15

Microbiota in Alcohol-Associated Organ Damage

Harberts, A., & Schnabl, B. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.05.012 · Cited by 16

Rifaximin for the Management of Colonic Diverticular Disease: far Beyond a Simple Antibiotic

Tursi, A., Scarpignato, C., Brandimarte, G., Mario, F. D., & Lanas, Á. (2018) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.274.rif · Cited by 14

The Human Microbiome in Health and Disease

Arnold, W., Hill, E. S., Fei, N., Yee, A. L., Garcia, M. S., Cralle, L. E., & Gilbert, J. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_39 · Cited by 14

Salivary microbiota‐immune profiling in cirrhosis: Could this be the noninvasive strategy that will revolutionize prognostication in hepatology?

Patel, V., & Shawcross, D. L. (2015) · Hepatology · doi:10.1002/hep.27870 · Cited by 14

New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target

Xing, Y., Ou, Y., Wang, Y., Hou, L., & Zhu, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117284 · Cited by 13

Hepatic Encephalopathy in Cirrhotic Patients and Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta‐Analysis

Feng, X., Li, X., Zhang, X., Chen, W., Tian, Y., Yang, Q., Yang, Y., Pan, H., & Jiang, Z. (2022) · BioMed Research International · doi:10.1155/2022/2469513 · Cited by 13

Implications of anaemia and response to anaemia treatment on outcomes in patients with cirrhosis

Rashidi‐Alavijeh, J., Nuruzade, N., Frey, A., Huessler, E., Hörster, A., Zeller, A. C., Schütte, A., Schmidt, H., Willuweit, K., & Lange, C. M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100688 · Cited by 14

Is there a role for microbiome-based approach in common variable immunodeficiency?

Poto, R., Ianiro, G., de Paulis, A., Spadaro, G., Marone, G., Gasbarrini, A., & Varricchi, G. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01006-3 · Cited by 16

Minimal Hepatic Encephalopathy

Redfield, R. L., Latt, N. L., & Muñoz, S. J. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.01.004 · Cited by 13

The future of clinical trials of gut microbiome therapeutics in cirrhosis

Bloom, P. P., & Chung, R. T. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101234 · Cited by 15

Effect of Rifaximin Treatment on Endotoxemia and Insulin Sensitivity in Humans

Finlin, B. S., Zhu, B., Boyechko, T., Westgate, P. M., Chia, C. W., Egan, J. M., & Kern, P. A. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00148 · Cited by 12

Management of Covert Hepatic Encephalopathy

Mullen, K. D., & Prakash, R. K. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2011.12.006 · Cited by 13

Microbiome

Reuter, B., & Bajaj, J. S. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.04.006 · Cited by 13

Regulating Intestinal Microbiota in the Prevention and Treatment of Alcohol-Related Liver Disease

Chi, X., Pan, C. Q., Liu, S., Cheng, D., Cao, Z., & Xing, H. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/6629196 · Cited by 13

Hepatic Encephalopathy Involves Interactions Among the Microbiota, Gut, Brain

Victor, D. W., & Quigley, E. M. M. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.022 · Cited by 12

Management of liver disease and portal hypertension in common variable immunodeficiency (CVID)

Baumert, L. S., Shih, A. R., & Chung, R. T. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100882 · Cited by 12

Malaria zoonosis in relation to malaria eradication.

Bruce-Chwatt, L. J. (1968) · PubMed · Cited by 12

Altered gut microbiota is associated with sleep disturbances in patients with minimal hepatic encephalopathy caused by hepatitis B-related liver cirrhosis

Luo, M., Hu, F.-R., Xin, R., Yao, L., Hu, S., & Bai, F. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2111300 · Cited by 13

Rifaximin stimulates nitrogen detoxification by PXR ‐independent mechanisms in human small intestinal organoids

de Wit, K., Beuers, U. H., Mukha, A., Stigter, E. C. A., Gülersönmez, M. C., Pittol, J. M. R., Middendorp, S., Takkenberg, R. B., & van Mil, S. W. C. (2022) · Liver International · doi:10.1111/liv.15491 · Cited by 11

Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure

Saeidinejad, M., Shabrawi, A. E., Sriphoosanaphan, S., Andreola, F., Mehta, G., Agarwal, B., & Jalan, R. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-1776773 · Cited by 12

Exploring the Prevalence, Predictors, and Impact of Bacterial Infections to Guide Empiric Antimicrobial Decisions in Cirrhosis (EPIC-AD)

Garg, P., Verma, N., Angrup, A., Taneja, N., Valsan, A., Reddy, V. D., Agarwal, J., Chaudhary, R., Kaur, P., Rathi, S., et al. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101352 · Cited by 11

Prophylaxis of hepatic encephalopathy: current and future drug targets

Maharshi, S., & Sharma, B. C. (2024) · Hepatology International · doi:10.1007/s12072-024-10647-9 · Cited by 11

Modulation of brain energy metabolism in hepatic encephalopathy: impact of glucose metabolic dysfunction

Prasad, S. K., Acharjee, A., Singh, V. V., Trigun, S. K., & Acharjee, P. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01407-7 · Cited by 11

Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation

Айтбаев, К. А., Murkamilov, I. T., & Fomin, V. V. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017898120-128 · Cited by 11

Diagnosis and management of hepatic encephalopathy

Shawcross, D. L. (2018) · British Journal of Nursing · doi:10.12968/bjon.2018.27.sup3.s7 · Cited by 11

Influence of Gut Microbiota on Behavior and Its Disturbances

Ignatova, V. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85317 · Cited by 13

Role of peripheral inflammation in minimal hepatic encephalopathy

Llansola, M., Izquierdo‐Altarejos, P., Montoliú, C., Mincheva, G., Palomares-Rodriguez, A., Pedrosa, M. A., Arenas, Y. M., & Felipo, V. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01417-5 · Cited by 10

Gut microbiota in the development and progression of chronic liver diseases: Gut microbiota-liver axis

Yakut, A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i3.104167 · Cited by 11

Microbiome and gut-liver interactions: From mechanisms to therapies

Anis, M. A., Shahid, Y., Majeed, A. A., & Abid, S. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i40.111409 · Cited by 12

Metabolomics in the understanding and management of hepatic encephalopathy

Pelle, J., Castelli, F. A., Rudler, M., Alioua, I., Colsch, B., Fenaille, F., Junot, C., Thabut, D., & Weiss, N. (2021) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114477 · Cited by 10

From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes

Widjaja, F., & Rietjens, I. M. C. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102658 · Cited by 12

Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?

Henderson, P. K., & Herrera, J. L. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.04.002 · Cited by 10

Susceptibilidad a la rifaximina y otros antimicrobianos de bacterias aisladas en pacientes con infecciones gastrointestinales agudas en el sureste de México

Novoa-Farías, O., Frati-Munari, A. C., Peredo, M. A., Flores-Juárez, S., Novoa-García, O., Galicia-Tapia, J., & Romero-Carpio, C. E. (2017) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2016.10.006 · Cited by 10

Effects of the antibiotic rifaximin on cortical functional connectivity are mediated through insular cortex

Sometti, D., Ballan, C., Wang, H., Braun, C., & Enck, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-83994-4 · Cited by 11

Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders

Vincenzo, F. D., Nicoletti, A., Negri, M., Vitale, F., Verme, L. Z. D., Gasbarrini, A., Ponziani, F. R., & Cerrito, L. (2023) · Antibiotics · doi:10.3390/antibiotics12061068 · Cited by 9

Antibiotic resistance in patients with liver cirrhosis: Prevalence and current approach to tackle

Liakina, V. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i31.7530 · Cited by 8

Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico

Novoa-Farías, O., Frati-Munari, A. C., Peredo, M. A., Flores-Juárez, S., Novoa-García, O., Galicia-Tapia, J., & Romero-Carpio, C. E. (2017) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2017.03.012 · Cited by 9

Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use

Williams, B., Green, S. J., Bosch, R. J., Chan, E. S., Jacobson, J. M., Margolis, D. M., Engen, P. A., LANDAY, A. L., & Wilson, C. C. (2019) · Pathogens and Immunity · doi:10.20411/pai.v4i2.290 · Cited by 9

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis

Kawaguchi, T., & Torimura, T. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0246 · Cited by 9

Papel de la rifaximina en el tratamiento de la encefalopatía hepática

Sánchez‐Delgado, J., & Miquel, M. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.08.003 · Cited by 9

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile

Gupta, K., Ghuman, H. S., & Handa, S. (2017) · Clinical Medicine Insights Gastroenterology · doi:10.1177/1179552217728905 · Cited by 12

Components from Curcuma longa (Turmeric) Against Hepatobiliary Diseases Based on Gut–Liver Axis: Pharmacotherapeutic Properties and Potential Clinical Applications

Gao, T., Wang, S., Zhu, Z., Lin, L., Luo, Y., Lu, M., & Liao, W. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500162 · Cited by 8

Gut microbiota: the indispensable player in neurodegenerative diseases

Li, S., Cai, Y., Wang, S., Luo, L., Zhang, Y., Huang, K., & Guan, X. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13509 · Cited by 11

The burden of hepatic encephalopathy and the use of albumin as a potential treatment

Bajaj, J. S., Pompili, E., & Caraceni, P. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101751 · Cited by 8

The Interplay of Cross‐Organ Immune Regulation in Inflammation and Cancer

Dou, J., Jiang, J., Xue, Y., Jiang, X., Jiang, Y., Xiao, P., & Xu, J. (2025) · MedComm · doi:10.1002/mco2.70249 · Cited by 9

Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy

Direkze, S., & Jalan, R. (2015) · Digestive Diseases · doi:10.1159/000375350 · Cited by 8

A bélflóra patofiziológai jelentősége és szerepe mint terápiás célpont májbetegségekben

Hagymási, K., Bacsárdi, A., Egresi, A., Berta, E., Tulassay, Z., & Lengyel, G. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.31178 · Cited by 8

The impact of antibiotics on the metabolic status of obese adults without bacterial infection: a systematic review and meta-analysis

Yoshida, N., Saito, Y., Tsujimoto, Y., Taito, S., Banno, M., Kataoka, Y., Yamashita, T., & Hirata, K. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1007a · Cited by 7

The effects of antibiotics and illness on gut microbial composition in the fawn-footed mosaic-tailed rat (Melomys cervinipes)

Rymer, T. L., & Pillay, N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281533 · Cited by 7

Sterile Fecal Filtrate From A Healthy Donor Improves Microbial Diversity In Patients With Hepatic Encephalopathy

Gedgaudas, R., Bajaj, J. S., Skiecevičienė, J., Valantienė, I., Kiudeliene, E., Bang, C., Franke, A., Schreiber, S., & Kupčinskas, J. (2023) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4906 · Cited by 7

Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity

Casanova‐Ferrer, F., Gallego, J., Fiorillo, A., Urios, A., Ríos, M.-P., León, J. L., Ballester, M. P., Escudero‐García, D., Kosenko, E. A., Belloch, V., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04844-7 · Cited by 7

194 THROMBELASTOGRAPHY BEFORE INVASIVE PROCEDURES REDUCES HEMODERIVATES REQUIREMENT IN CIRRHOTIC PATIENTS WITH COAGULATION DISORDERS. A RANDOMIZED CONTROLLED TRIAL

Pietri, L. D., Bianchini, M. A., Montalti, R., Maira, T. D., Maria, N. D., Begliomini, B., Gerunda, G. E., & Villa, E. (2013) · Journal of Hepatology · doi:10.1016/s0168-8278(13)60196-8 · Cited by 4

Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with rifaximin in cirrhosis: implications for the gut-liver-brain axis

Ahluwalia, V., Wade, J. B., Heuman, D. M., Hammeke, T. A., Sanyal, A. J., Sterling, R. K., Stravitz, R. T., Luketic, V., Siddiqui, M. S., Puri, P., et al. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9507-6 · Cited by 92

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

Kaji, K., Takaya, H., Saikawa, S., Furukawa, M., Sato, S., Kawaratani, H., Kitade, M., Moriya, K., Namisaki, T., Akahane, T., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i47.8355 · Cited by 107

Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis

Bajaj, J. S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13435 · Cited by 127

The role of microbiota in hepatic encephalopathy

Bajaj, J. S. (2014) · Gut Microbes · doi:10.4161/gmic.28684 · Cited by 181